Backed by a handful of prominent investors including the Gates Foundation, the startup is pursuing an approach it believes ...

Despite being unable to declare statistical success, the company claimed its therapy showed enough promise to support moving ...

The gene therapy developer has lost most of its value since going public in 2020 and saw a long road ahead for a delivery ...

The approval could help Enhertu, which is already a multibillion-dollar seller, supplant a regimen that’s been the standard ...

Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple ...

A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another ...

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

Using a kind of novel linker technology, the startup is developing versions of incretin and non-incretin therapies that can ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

An unusual tussle over the availability of funds for Apple Tree’s startups led the firm to seek protection from creditors ...

A high-stakes meeting with wide-ranging public health implications again didn’t result in a vote, as members struggled to ...

Hemophilia gene therapies arrived a few years ago with blockbuster expectations. But now, one therapy has been pulled from ...